Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
A J Marcus, … , R B Gayle, C R Maliszewski
A J Marcus, … , R B Gayle, C R Maliszewski
Published March 15, 1997
Citation Information: J Clin Invest. 1997;99(6):1351-1360. https://doi.org/10.1172/JCI119294.
View: Text | PDF
Research Article Article has an altmetric score of 9

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.

  • Text
  • PDF
Abstract

We previously demonstrated that when platelets are in motion and in proximity to endothelial cells, they become unresponsive to agonists (Marcus, A.J., L.B. Safier, K.A. Hajjar, H.L. Ullman, N. Islam, M.J. Broekman, and A.M. Eiroa. 1991. J. Clin. Invest. 88:1690-1696). This inhibition is due to an ecto-ADPase on the surface of endothelial cells which metabolizes ADP released from activated platelets, resulting in blockade of the aggregation response. Human umbilical vein endothelial cells (HUVEC) ADPase was biochemically classified as an E-type ATP-diphosphohydrolase. The endothelial ecto-ADPase is herein identified as CD39, a molecule originally characterized as a lymphoid surface antigen. All HUVEC ecto-ADPase activity was immunoprecipitated by monoclonal antibodies to CD39. Surface localization of HUVEC CD39 was established by confocal microscopy and flow cytometric analyses. Transfection of COS cells with human CD39 resulted in both ecto-ADPase activity as well as surface expression of CD39. PCR analyses of cDNA obtained from HUVEC mRNA and recombinant human CD39 revealed products of the same size, and of identical sequence. Northern blot analyses demonstrated that HUVEC express the same sized transcripts for CD39 as MP-1 cells (from which CD39 was originally cloned). We established the role of CD39 as a prime endothelial thromboregulator by demonstrating that CD39-transfected COS cells acquired the ability to inhibit ADP-induced aggregation in platelet-rich plasma. The identification of HUVEC ADPase/CD39 as a constitutively expressed potent inhibitor of platelet reactivity offers new prospects for antithrombotic therapeusis.

Authors

A J Marcus, M J Broekman, J H Drosopoulos, N Islam, T N Alyonycheva, L B Safier, K A Hajjar, D N Posnett, M A Schoenborn, K A Schooley, R B Gayle, C R Maliszewski

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1990 1983 Total
Citations: 1 2 3 3 3 5 3 3 8 15 7 5 12 12 33 10 8 10 13 10 21 22 19 24 22 18 14 21 3 1 1 332
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2016 (15)

Title and authors Publication Year
Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in MiceHighlights
R Covarrubias, E Chepurko, A Reynolds, ZM Huttinger, R Huttinger, K Stanfill, DG Wheeler, T Novitskaya, SC Robson, KM Dwyer, PJ Cowan, RJ Gumina
Arteriosclerosis, thrombosis, and vascular biology 2016
Platelet signaling: a complex interplay between inhibitory and activatory networks
AP Bye, AJ Unsworth, JM Gibbins
Journal of Thrombosis and Haemostasis 2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Calcium Entry Pathways in Non-excitable Cells
JA Rosado
2016
Complement inhibition in biomaterial- and biosurface-induced thromboinflammation
KN Ekdahl, S Huang, B Nilsson, Y Teramura
Seminars in Immunology 2016
Biomolecular strategies to modulate the macrophage response to implanted materials
YK Kim, EY Chen, WF Liu
Journal of Materials Chemistry B 2016
Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection:
XY Cai, XC Ni, Y Yi, HW He, JX Wang, YP Fu, J Sun, J Zhou, YF Cheng, JJ Jin, J Fan, SJ Qiu
Medicine 2016
Platelet proteomics applied to the search for novel antiplatelet therapeutic targets
I Izquierdo, Á García
Expert Review of Proteomics 2016
Rapid Evaluation of Platelet Function With T2 Magnetic Resonance
A Cuker, H Husseinzadeh, T Lebedeva, JE Marturano, W Massefski, TJ Lowery, MP Lambert, CS Abrams, JW Weisel, DB Cines
American Journal of Clinical Pathology 2016
High expression of CD39 in gastric cancer reduces patient outcome following radical resection
XY Cai, XF Wang, J Li, JN Dong, JQ Liu, NP Li, B Yun, RL Xia, J Qin, YH Sun
Oncology Letters 2016

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 27 patents
111 readers on Mendeley
See more details